Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease [8]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1574-1576

  Zhao, W ^a   Bueso Ramos, C E ^a   Verstovsek, S ^a   Barkoh, B A ^a   Khitamy, A A ^a   Jones, D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEM CELL FACTOR;

ADULT; AGED; BONE MARROW BIOPSY; BONE MARROW CELL; CELL COUNT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CODON; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DNA FINGERPRINTING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; MAST CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS;

EID: 34250706238     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404680     Document Type: Letter

References (8)

1. Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P et al. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: Expression of stem cell factor by lesional mast cells. Am J Clin Pathol 2002; 118: 242-247.
2. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-314.
3. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
4. Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG et al. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004; 6: 335-342.
5. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
6. Valent P, Metcalfe DD, Horny H-P, Parwaresch RM, Li CY, Bennett JM et al. Mastocytosis. In: Jaffe ES, Harris N, Stein H & Vardiman JW (eds) Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, 292-302.
7. Nordstrom T, Ronaghi M, Forsberg L, de Faire U, Morgenstern R, Nyren P. Direct analysis of single-nucleotide polymorphism on double-stranded DNA by pyrosequencing. Biotechnol Appl Biochem 2000; 31 (Pt 2): 107-112.
8. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481.